We next examined the sensitivity of these cancer and noncancer cells to prolonged exposure to agents targeting the xCT and GPX4 anti-ferroptotic machinery, Erastin and Rsl-3 (Figure 4a). This evidence concerns the gene GPX4 and cancer.